Cargando…

CD38‐Specific CAR Integrated into CD38 Locus Driven by Different Promoters Causes Distinct Antitumor Activities of T and NK Cells

The robust and stable expression of CD38 in T‐cell acute lymphoblastic leukemia (T‐ALL) blasts makes CD38 chimeric antigen receptor (CAR)‐T/natural killer (NK) a potential therapy for T‐ALL. However, CD38 expression in normal T/NK cells causes fratricide of CD38 CAR‐T/NK cells. Here a “2‐in‐1” gene...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liao, Chan, Wang, Yajie, Huang, Yanjie, Duan, Yanting, Liang, Yan, Chen, Jiangqing, Jiang, Jie, Shang, Kai, Zhou, Chun, Gu, Ying, Liu, Nan, Zeng, Xun, Gao, Xiaofei, Tang, Yongmin, Sun, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520621/ https://www.ncbi.nlm.nih.gov/pubmed/37485647 http://dx.doi.org/10.1002/advs.202207394

Ejemplares similares

High-affinity CD16 integration into a CRISPR/Cas9-edited CD38 locus augments CD38-directed antitumor activity of primary human natural killer cells
por: Clara, Joseph Andrew, et al.
Publicado: (2022)

CAR-T cells targeting CD38 and LMP1 exhibit robust antitumour activity against NK/T cell lymphoma
por: Li, Hongwen, et al.
Publicado: (2023)

Regulation of CD38 on Multiple Myeloma and NK Cells by Monoclonal Antibodies
por: Wu, Hao-Tian, et al.
Publicado: (2022)

CD38(+)CD39(+) NK cells associate with HIV disease progression and negatively regulate T cell proliferation
por: Qian, Shi, et al.
Publicado: (2022)

The role of CD38 in HIV infection
por: Lu, Liqi, et al.
Publicado: (2021)

Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design
por: Drent, Esther, et al.
Publicado: (2018)

NK cells and CD38: Implication for (Immuno)Therapy in Plasma Cell Dyscrasias
por: Zambello, Renato, et al.
Publicado: (2020)

A second‐generation CD38‐CAR‐T cell for the treatment of multiple myeloma
por: Li, Hongwen, et al.
Publicado: (2023)

Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting
por: Viola, Domenico, et al.
Publicado: (2020)

CD38 in Neurodegeneration and Neuroinflammation
por: Guerreiro, Serge, et al.
Publicado: (2020)

P1378: CAR-T CELLS TARGETING CD38 AND LMP1 EXHIBIT ROBUST ANTI-TUMOR ACTIVITY AGAINST NK/T-CELL LYMPHOMA
por: Hongwen, LI, et al.
Publicado: (2023)

Responses of CD27(+)CD38(+) plasmablasts, and CD24(hi)CD27(hi) and CD24(hi)CD38(hi) regulatory B cells during primary dengue virus 2 infection
por: Lei, Chenshuang, et al.
Publicado: (2021)

CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond
por: Roccatello, Dario, et al.
Publicado: (2020)

Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?
por: Plesner, Torben, et al.
Publicado: (2020)

Phenotyping and Target Expression Profiling of CD34(+)/CD38(−) and CD34(+)/CD38(+) Stem- and Progenitor cells in Acute Lymphoblastic Leukemia
por: Blatt, Katharina, et al.
Publicado: (2018)

High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma
por: Tang, Yuanyan, et al.
Publicado: (2022)

CD38 in Advanced Prostate Cancers
por: Guo, Christina, et al.
Publicado: (2021)

Targeting CD38 for acute leukemia
por: Zhong, Xushu, et al.
Publicado: (2022)

A distinct CD38(+)CD45RA(+) population of CD4(+), CD8(+), and double-negative T cells is controlled by FAS
por: Maccari, Maria Elena, et al.
Publicado: (2020)

EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma
por: Chemlal, Djamila, et al.
Publicado: (2023)

Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma Against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant
por: Holthof, Lisa C., et al.
Publicado: (2021)

Signaling Dynamics of TSHR-Specific CAR-T Cells Revealed by FRET-Based Biosensors
por: Zhou, Jing, et al.
Publicado: (2022)

Interferon gamma selectively inhibits very primitive CD342+CD38- and not more mature CD34+CD38+ human hematopoietic progenitor cells
Publicado: (1994)

A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
por: Mei, Heng, et al.
Publicado: (2021)

Distinct physical condition and social behavior phenotypes of CD157 and CD38 knockout mice during aging
por: Gerasimenko, Maria, et al.
Publicado: (2020)

CD27(hi)CD38(hi) plasmablasts are activated B cells of mixed origin with distinct function
por: Rouers, Angeline, et al.
Publicado: (2021)

Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model
por: Zannetti, Beatrice Anna, et al.
Publicado: (2020)

CD38: T Cell Immuno-Metabolic Modulator
por: Kar, Anwesha, et al.
Publicado: (2020)

Roles of CD38 in the Immune Response to Infection
por: Glaría, Estibaliz, et al.
Publicado: (2020)

CD38: An Immunomodulatory Molecule in Inflammation and Autoimmunity
por: Piedra-Quintero, Zayda L., et al.
Publicado: (2020)

Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38(+) tumors in mouse models in vivo
por: Fumey, William, et al.
Publicado: (2017)

Case report: CD38-directed CAR-T cell therapy: A novel immunotherapy targeting CD38- positive blasts overcomes TKI and chemotherapy resistance of myeloid chronic myeloid leukemia in blastic phase
por: Cui, Qingya, et al.
Publicado: (2022)

CD38, CD157, and RAGE as Molecular Determinants for Social Behavior
por: Higashida, Haruhiro, et al.
Publicado: (2019)

P808: CONTROLLED FRATRICIDE TO AUGMENT ANTI-MYELOMA REACTIVITY OF SLAMF7 AND CD38 CAR T CELLS
por: Konetzki, Verena, et al.
Publicado: (2023)

CD38 Drives Progress of Osteoarthritis by Affecting Cartilage Homeostasis
por: Ma, Jin‐jin, et al.
Publicado: (2022)

Increased Activity of a NK-Specific CAR-NK Framework Targeting CD3 and CD5 for T-Cell Leukemias
por: Voynova, Elisaveta, et al.
Publicado: (2022)

Decreased levels of T follicular helper (CD4+CXCR5+) cells and CD27+CD38+ and CD27+CD38− B cells in ankylosing spondylitis patients correlate with markers of inflammation
por: Lejon, Kristina, et al.
Publicado: (2022)

Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation
por: Costa, Federica, et al.
Publicado: (2017)

Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma
por: Fayon, Maxime, et al.
Publicado: (2021)

Proteomic Profiling Identifies Distinct Protein Patterns in Acute Myelogenous Leukemia CD34+CD38- Stem-Like Cells
por: Kornblau, Steven M., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_fe155c83kqh54rpnueh9qr69go